<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T04:15:15Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/22422" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/22422</identifier><datestamp>2026-09-24T06:34:23Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Bhatia, Mick</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Ye, Wenqing</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Biochemistry and Biomedical Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2017-11-28T19:55:49Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2017-11-28T19:55:49Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2017-11-16</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/22422</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/13892</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">AML is a cancer of the blood and bone marrow characterized by the presence of&#xd;
highly proliferative and abnormally differentiated myeloblasts. Previous work from the&#xd;
Bhatia lab utilized the orthotopic xenograft model in order to isolate a population of&#xd;
leukemic regenerating cells (LRC) that exists prior to relapse. Affymatrix analysis of LRCs&#xd;
revealed up-regulation of 248 genes that can act as unique targets to prevent relapse. In&#xd;
order to screen compounds against all 248 targets, it is important to develop an in vitro&#xd;
model that is able to appropriately recapture the functional and molecular markers of&#xd;
LRCs. Primary AML samples were treated with 5-doses of 0.15 μM, 1 μM AraC, or DMSO&#xd;
control and several outcomes were measured. In vitro AraC treatment was not able to&#xd;
recapitulate the progenitor frequency curve and CD34 expression curve observed in vivo.&#xd;
Additionally, we were not able to see a consistent increase in select LRC targets DRD2,&#xd;
GLUT2, FUT3, and FASL via flow cytometry. Despite an increase in the mRNA levels of&#xd;
LRC genes 24h after treatment with 0.15 μM AraC, long term analysis could not be&#xd;
completed due to poor RNA quality and low expression of LRC-targets. Primary AML cells&#xd;
were co-culture with mouse MS-5 stromal cell line order to study the effects of&#xd;
mesenchymal stromal cells on AML response to AraC. Co-culture with MS-5 cells had&#xd;
different effects on select primary AML cells. AML 14939 showed an increase in CD34&#xd;
and LRC targets DRD2 and FUT3 following AraC treatment when co-cultured with MS-5&#xd;
cells; while A374 showed no differences between DMSO and AraC treated groups.&#xd;
Overall, these findings suggest the LRC signature is not induced by treatment with AraC&#xd;
alone. Complex interactions between AML cells and their bone marrow niche during AraC&#xd;
treatment plays an important role in the development of LRCs prior to AML relapse.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Master of Science (MSc)</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="layabstract" lang="en_US">AML is a cancer of blood cells characterized by the presence of rapidly dividing&#xd;
cancer cells termed myeloblasts. AML has a high rate of disease relapse. The Bhatia lab&#xd;
modelled AML relapse in a mouse and discovered an unique population of cells that exist&#xd;
prior to relapse termed LRCs. LRCs express distinctive genes that can act as targets for&#xd;
the development of new therapies to prevent relapse. In order to screen potential relapse preventing compounds, we set out to recapture AML relapse using cells in a dish. AML&#xd;
cells from patients were treated with chemotherapy reagent AraC and the number of&#xd;
cancer progenitors and the expression of specific LRC proteins were measured. AraC did&#xd;
not increase the level of 3 out of 4 LRC proteins studied. We determined the LRCs were&#xd;
not caused by AraC treatment, and the physiology of the bone marrow environment plays&#xd;
an important role in inducing relapse.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Acute Myeloid Leukemia</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Relapse</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Therapeutic Resistance</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">In vitro Modeling</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">Development of an in vitro Relapse Model for Identification of Novel Therapeutics in Acute Myeloid Leukemia</dim:field>
   <dim:field mdschema="dc" element="title" qualifier="alternative" lang="en_US">Development of an in vitro Relapse Model for AML</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>